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The fluorinated benzothiazole analogue 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is a novel agent
with potent and selective antitumour properties and, in the form of its L-lysylamide prodrug Phortress (NSC 710305), is a current
candidate for early phase clinical studies. Previous findings have indicated that cytochrome P450 1A1 (CYP1A1) may play a role in the
antitumour activity of molecules in the benzothiazole series including the nonfluorinated parent compound 2-(4-amino-3-
methylphenyl)benzothiazole (DF 203, NSC 674495) (Kashiyama et al, 1999; Chua et al, 2000; Loaiza-Pe ´rez et al, 2002). In this study,
we assessed and verified that a fully functional aryl hydrocarbon receptor (AhR) signalling pathway is a necessary requisite for the
induction of efficient cytotoxicity by 5F 203 in MCF-7 wild-type sensitive cells. Drug exposure caused MCF-7 sensitive cells to arrest
in G1 and S phase, and induced DNA adduct formation, in contrast to AhR-deficient AH
R100 variant MCF-7 cells. In sensitive MCF-7
cells, induction of CYP1A1 and CYP1B1 transcription (measured by luciferase reporter assay and real-time reverse transcriptase-
polymerase chain reaction (RT–PCR)), and 7-ethoxyresorufin-O-deethylase (EROD) activity was demonstrated, following treatment
with 5F 203. In contrast, in resistant AH
R100 cells, drug treatment did not affect CYP1A1 and CYP1B1 transcription and EROD activity.
Furthermore, AH
R100 cells failed to produce either protein/DNA complexes on the xenobiotic responsive element (XRE) sequence
of CYP1A1 promoter (measured by electrophoretic mobility shift assay) or DNA adducts. The data confirm that activation of the AhR
signalling pathway is an important feature of the antitumour activity of 5F 203.
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2-(4-Amino-3-methylphenyl)benzothiazoles are novel compounds
with potent and unique antitumour properties (Shi et al, 1996;
Bradshaw et al, 1998a,b; Kashiyama et al, 1999). It was
demonstrated that selective metabolism in vitro of the parent
agent DF 203 (NSC 674495) correlated very highly with its
antiproliferative activity, with uptake and biotransformation
observed only in those cell lines that are sensitive to the
compound, such as MCF-7 and T47D breast carcinoma cells
(Kashiyama et al, 1999). CYP1A1, whose expression and activity
are induced only in sensitive cells, appears to be responsible for
the metabolic hydroxylation of DF 203 in position 6, which
produces an inactive and antagonistic molecule (Chua et al, 2000).
CYP1A1 is also postulated to have a crucial role in mediating the
antitumour activity of DF 203, possibly generating an electrophilic
intermediate responsible for the formation of DNA adducts in
sensitive cells (Stevens et al, 2001).
Fluorinated derivatives of the parent drug DF 203 (see Figure 1
for structures) were synthesised in order to prevent deactivation
resulting from metabolic ring hydroxylation (Hutchinson et al,
2001). Fluoro-analogues retain potency and selectivity, and
successfully reduce or abolish the production of inactive and
antagonistic metabolites and the consequent biphasic dose–
response phenomenon. Drug-induced induction of CYP1A1, a
crucial event in determining the antitumour specificity of this
series of benzothiazoles (Chua et al, 2000), was not compromised
by fluorination (Hutchinson et al, 2001).
2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC
703786) has emerged as the most potent of the new generation of
antitumour benzothiazoles both in vitro and in vivo and is currently
the focus of pharmaceutical and preclinical development, as it can be
converted to a readily soluble prodrug with appropriate pharma-
ceutical properties (Bradshaw et al, 2002).
As for the parent drug DF 203, depletion of 5F 203 from culture
media and subsequent induction of CYP1A1 correlate with cell
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sresponsiveness. Only in sensitive cells does drug uptake occur and
CYP1A1 enzyme expression increase to detectable levels; naturally
occurring drug-resistant cells do not show significant changes in
either drug levels in medium or CYP1A1 expression (Brantley et al,
2001).
We have previously reported that the parent compound DF 203
induces activation of the AhR in sensitive cells such as human
breast epithelial cancer MCF-7 cells. In contrast, nonresponsive
cells, for example, breast carcinoma MDA-MB-435 or prostate
carcinoma PC-3 cells, showed no activation of the AhR and no
induction of CYP1A1 after drug treatment (Loaiza-Pe ´rez et al,
2002). We also have reported a suitable model to investigate the
role of the AhR in mediating drug cytotoxicity (Loaiza-Pe ´rez et al,
2001), consisting of AhR-deficient AH
R100 cells, derived from
MCF-7 human breast epithelial cancer cells by continuous
exposure to escalating concentrations of benzo[a]pyrene (Yeh
et al, 2001). AH
R100 cells display relative resistance to the cytotoxic
effects of several polycyclic aromatic hydrocarbons (PAHs), such
as benzo[a]pyrene and dimethylbenz[a]anthracene (DMBA), due
to impairment of the AhR signal transduction pathway (Yeh et al,
2001; Ciolino et al, 2002).
We therefore have used wild-type MCF-7 and AH
R100 cells as a
model, to investigate the molecular determinants for sensitivity to
the clinical candidate 5F 203, including toxicity, cell cycle
distribution, DNA damage, CYP1A1 activity and AhR signalling
pathway activation. The results presented in this paper confirm
that activation of the AhR plays an essential role in 5F 203
antitumour activity, mediating responsiveness and efficacy.
MATERIALS AND METHODS
Drug and cell culture
5F 203 was synthesised by the Cancer Research Laboratories at the
University of Nottingham, UK and the Drug Synthesis and
Chemistry Branch, NCI, following published methods (Hutchinson
et al, 2001). The compound was dissolved in DMSO to make a
100mM stock concentration and further diluted to the working
concentration (1nM–100mM) for experimental procedures. 2,3,7,8-
Tetrachlorodibenzo-p-dioxin (TCDD) was prepared as 10mM top
stock dissolved in DMSO and diluted to the working concentration
(10nM) immediately prior to use. MCF-7 cells were obtained from
the National Cancer Institute Repository (National Cancer
Institute-Frederick Cancer Research and Development Center,
Frederick, MD, USA) and grown in RPMI 1640 medium
supplemented with 10% fetal bovine serum (FBS) (Invitrogen,
Carlsbad, CA, USA). AhR-deficient AH
R100 cells were generated
from wild-type MCF-7 cells by 6–9-month exposure to benzo[a]-
pyrene and subsequently demonstrated a 100-fold higher resis-
tance to benzo[a]pyrene than the wild-type line. Additional
characterisation indicated that AH
R100 cells contained reduced
amounts of AhR and normal levels of the aryl hydrocarbon
receptor nuclear translocator (ARNT) (Ciolino et al, 2002).
Assessment of cytotoxicity
Cells were inoculated in 96-well plates and maintained for 24h
before treatment with 5F 203, which consisted of five serial
dilutions (1:10) ranging from 10nM to 100mM. Treated cells were
subsequently maintained for an additional 48h, and cellular
protein was measured by the sulphforhodamine-B (SRB) assay as
described previously (Monks et al, 1991). Briefly, cells were fixed
with trichloroacetic acid and stained with SRB. Protein-bound SRB
was solubilised and measured spectrophotometrically to determine
relative cell viability in treated and untreated cells.
4,6-Diamidino-2-phenylindole (DAPI) staining
Approximately 2 10
5 cells were grown on coverslips overnight.
Cells were exposed to DMSO (0.1%) or 5F 203 (1mM) for 24h.
Floating cells contained in the supernatant were collected by
cytocentrifugation, and stained with 0.4% DAPI. Experiments were
repeated at least three times. Stained cells were then visualised on a
Zeiss Axiovert microscope using  63 objective and images were
captured with an Optronics CCD camera (Loaiza-Pe ´rez et al, 2002).
32P-postlabelling assay
Pellets of control and treated (0.1% DMSO or 1mM 5F 203 for 24h)
MCF-7 and AH
R100 cells were used for DNA extraction using
Qiagen DNA extraction columns according to the manufacturer’s
protocol. Of each extracted DNA 5mg was digested to deoxynucleo-
side 30-monophosphates by incubating with micrococcal nuclease
(175mU) and calf-spleen phosphodiesterase (6mU) at 371C
overnight. DNA adduct enrichment was carried out by butanol
extraction (Gupta, 1985). Adducts were then radiolabelled by 50-
phosphorylation using 62.5mCi of [g-
32P]ATP and 5U of T4
polynucleotide kinase.
HPLC detection and quantification of DNA adducts
32P-labelled products were separated on a Hypersil BDS C18
analytical column (250 4.6mm, 5mm; Shandon). The mobile
phase consisted of 88% 2 M ammonium formate (pH 4.0) and 12%
acetonitrile for 50min, followed by a linear gradient of 20–45%
acetonitrile for 15min. Radioactivity was monitored by a radio-
chemical detector (Lab Logic, b-RAM) lined to a Varian Star 9012
pump. Data analysis was done by Laura, an MS Windows package
(Lab Logic Inc.). The relative adduct levels (RAL) were calculated
by the method of Reddy and Randerath (1986), based on the
specific activity of [g-
32P]ATP and the amount of DNA used. RAL
values were then translated into fmol adducts per mg DNA (Gupta,
1985).
Cell cycle analysis
Cell cycle analysis on MCF-7 and AH
R100 cells was performed as
described previously (Sherwood and Schimke, 1995). Briefly,
DF 203 (NSC 674495): R = H 
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Figure 1 Chemical structures of antitumour 2-(4-amino-3-methylphenyl)benzothiazoles.
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sexponentially growing cells were exposed to either DMSO (0.1%)
or 5F 203 (1mM) for 24h, then harvested, washed briefly, in cold
PBS and fixed in 70% ethanol. DNA was stained by incubating the
cells in PBS, containing propidium iodide (50mgml
 1) and
RNAase A (1mgml
 1) for 30min at 371C and fluorescence was
measured and analysed using FACSCaliber (Becton Dickinson
Immunocytometry Systems, San Jose ´, CA, USA) and ModFit
(Verity Software, Topsham, ME, USA).
CYP1A1 activity in intact MCF-7 and AH
R100 cells
MCF-7 and AH
R100 cells were grown in 24-well plates to 60–70%
confluence prior to treatment with 0.1% DMSO (control) or 5F 203
(1nM–1mM). At the end of the incubation period, the medium was
aspirated and the cells were washed with PBS. CYP1A1 enzyme
activity was subsequently determined by 7-ethoxyresorufin-O-
deethylase (EROD) activity in intact cells as described by Kennedy
and Jones (1994). Briefly, the fluorescence of resorufin generated
from the conversion of ethoxyresorufin by CYP1A1 was measured
spectrophotometrically and resorufin content was derived from a
standard curve.
Real-time RT–PCR
Evaluation of CYP1A1 and CYP1B1 gene expression in MCF-7 and
AH
R100 cells was performed by real-time RT–PCR, using 15 cycles
of PCR, primers and probes described in a previous report
(Loaiza-Pe ´rez et al, 2002). RNA was isolated using Qiagen kits
(Qiagen, Valencia, CA, USA). PCR efficiencies were validated by
means of a standard curve.
Transfections
Cells were transfected using LipofectAMINE (Invitrogen), with
0.5mg Renilla reniformis luciferase (pRL-TK) (Promega, Madison,
WI, USA), and 1.5mg of pTX.Dir or pT81 as described previously
(Loaiza-Pe ´rez et al, 2002). Luciferase activity was measured by the
Dual-Luciferase Assay System (Promega, Madison, WI, USA)
following the manufacturer’s instructions, and transfection effi-
ciency was monitored by the activity of the R. reniformis plasmid.
Electrophoretic mobility shift assay (EMSA)
Synthetic oligonucleotides containing the AhR-binding site of the
human CYP1A1 promoter (50-CTC CGG TCC TTC TCA CGC AAC
GCC TGG GCA-30) (Invitrogen) were used as probes. Electro-
phoretic mobility shift assays were performed as described
previously (Loaiza-Pe ´rez et al, 2002). Briefly, nuclear extracts
(20mg) from control (0.1% DMSO) and treated (1mM 5F 203 for
1h, or 10n M TCDD for 1h) MCF-7 and AH
R100 cells were
incubated in binding buffer with the [
32P]DNA probe and the
resulting DNA/protein DNA complexes were separated on a 6%
polyacrylamide gel (Novex) under nondenaturing conditions and
high ionic strength. Gels were dried and imaged by autoradio-
graphy.
RESULTS
5F 203-induced cytotoxicity correlates with AhR activation
in sensitive MCF-7 cells
Previous observations have shown that cytotoxicity of benzothia-
zoles is mediated via activation of the AhR signalling pathway
(Kashiyama et al, 1999; Chua et al, 2000; Loaiza-Pe ´rez et al, 2002).
In addition, cytotoxicity across a large panel of human tumour cell
lines correlates with CYP1A1 inducibility (Hose et al, 2001). We
then sought to investigate responsiveness of MCF-7 wild-type cells
to the clinical candidate 5F 203 as compared to that of MCF-7-
derived AhR-deficient cells (AH
R100). Specifically, we sought to
establish whether AhR-mediated signalling could account for all
the cytotoxic potential of this agent. Figure 2A indicates that MCF-
7 cells are sensitive to this compound (GI50¼121nM,4 8 h
exposure). In contrast, AH
R100 cells show a decreased growth
inhibition after treatment with high drug concentration
(GI504100mM) and can therefore be considered resistant.
Figure 2 (A) Selective cytotoxicity of 5F 203 to MCF-7 cells. Growth
inhibition induced by 5F 203 was assessed by sulphforhodamine B assay as
detailed in Materials and Methods. Values are means7s.d. (n¼10). (B)5 F
203 induces changes in nuclear morphology of 5F 203-sensitive MCF-7
breast cells but not AH
R100 cells. Cells prepared as described in Materials
and Methods were exposed for 24h to 0.1% DMSO (control) or 1mM 5F
203, and stained with 4,6-diamidino-2-phenylindole (DAPI).
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sAs a complementary approach, MCF-7 and AH
R100 cells treated
with 0.1% DMSO (control) or 5F 203 (1mM) for 1h were
subsequently stained by DAPI (Figure 2B). Only MCF-7 cells
treated with the drug showed altered nuclear morphology, which
included chromatin condensation and marginalisation to the
nuclear membrane. AH
R100 cells failed to show any significant
morphological changes. Taken together, Figure 2A and B suggests
that activation of the AhR signalling pathway participates in the
antiproliferative activity of 5F 203, which results in growth
inhibition and modified nuclear features.
5F 203 induces DNA adduct formation in MCF-7 cells
We next questioned whether DNA adducts could be produced in
MCF-7 and AhR-deficient AH
R100 cells. DMSO-treated MCF-7 and
AH
R100 cells showed a similar profile of DNA adducts, with a few
adducts eluting within the early retention time (p20min)
(Figure 3). After treatment with 1mM 5F 203, no significant
changes in these peaks were found in either cell lines, while several
other adducts with longer retention time were detected. The major
adduct formed in AH
R100 cells (adduct 17 in Figure 3Bii) is
chromatographically equivalent to an adduct detected in MCF-7
cells (adduct 7 in Figure 3Aii). Although DNA adduct profiles
appear similar in the two cell lines, the number of total adducts/10
8
nucleotides induced by drug treatment was greatly decreased in
AH
R100 cells compared to wild-type MCF-7 cells. These findings
suggest that impairment of the AhR signalling pathway may result
in reduced activation of 5F 203 into reactive species able to damage
DNA.
5F 203 causes altered cell cycle distribution
As our results in Figures 2 and 3 indicated that 5F 203 was
inducing the formation of DNA adducts, we investigated whether
this could result in an altered cell cycle profile. For this approach,
cells sensitive (MCF-7) and insensitive (AH
R100) to 5F 203 were
exposed to 1mM of the drug or 0.1% DMSO for 24h and
subsequently processed for cell cycle analysis. As illustrated in
Figure 4, 5F 203 treatment of MCF-7 cells caused a notable increase
in G1 (37 to 52%) and S (20 to 27%) phase cells, which coincided
with a decrease in G2/M (42 to 16%) phase cells. Accumulation of
cells in sub-G1 was minimal when compared to control. In
contrast, 5F 203-insensitive cells (AH
R100) failed to demonstrate
any notable effect on the cell cycle, in particular S, G2/M and sub-
G1 phases. The data demonstrate that 5F 203-induced DNA
damage may lead to cell accumulation in G1 and S phase
concomitant with growth inhibition. As MCF-7 cells are p53 wild
type, their response to 5F 203 treatment is consistent with the
operation of a G1- and possibly S-phase checkpoint to cell cycle
progression after DNA adduct formation.
CYP1A1 and CYP1B1 induction
5F 203 induces DNA damage and cell cycle arrest most obviously
in MCF-7 cells with a fully functional AhR signalling pathway. The
hypothesis that deficient activation of CYP1A1 might occur in
AhR-deficient AH
R100 cells was then addressed. The enzymatic
activity of CYP1A1 in intact MCF-7 and AH
R100 cells treated with
5F 203 was assayed by measuring EROD activity. Although both
CYP1A1 and CYP1B1 can catalyse the dealkylation of ethoxy-
resorufin, the specific activity of CYP1A1 is approximately 40-fold
higher than that of CYP1B1 (Doostdar et al, 2000). Incubation with
5F 203 for 24h resulted in a concentration-dependent increase in
EROD activity over a range of 50nM to 1mM in MCF-7 cells,
whereas the drug had no effect on EROD activity in AH
R100 cells
(Figure 5A).
In order to compare the effect of 5F 203 on CYP1A1 and CYP1B1
gene expression, MCF-7 and AH
R100 cells were treated with the
compound (1mM) for 24h and mRNA levels for these two genes
were measured by real-time RT–PCR. 5F 203 caused an increase in
the mRNA levels of both cytochromes in MCF-7 cells, where
relative levels of CYP1A1 mRNA were approximately 100-fold
higher when compared to control; only a minimal increase of
CYP1B1 mRNA (10-fold) was observed (Figure 5B). In contrast, in
AH
R100 cells, levels of CYP1A1 and CYP1B1 mRNA after treatment
remained similar to control (Figure 5B). These findings are in
agreement with previous studies which described that the parent
compound DF 203 causes induction of CYP1A1 protein and
increase in mRNA levels in MCF-7 cells but not in DF 203
inherently resistant cells (Chua et al, 2000; Loaiza-Pe ´rez et al,
2002).
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Figure 3 DNA adduct profiles in (A) MCF-7 and (B)A H
R100 cells. Cells were incubated with (i) 0.1% DMSO or (ii) 1mM 5F 203 for 24h.
32P-labelled
adducts were analysed using 2mg digested DNA on a Hypersil C18 column with a gradient of acetonitrile in 2 M ammonium formate as detailed in Materials
and Methods. The early peak is due to the presence of free [g-
32P]ATP.
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XRE sequence of CYP1A1 in MCF-7 but not AH
R100 cells
CYP1A1 and CYP1B1 promoters are regulated by the AhR, which
forms a heterodimer with ARNT. Binding of the complete dimer to
the XREs in the promoter region mediates transcription of AhR-
responsive genes, including CYP1A1 and CYP1B1 (Whitlock,
1999). MCF-7 and AH
R100 cells were transfected with an XRE-
luciferase reporter construct (pTX.Dir); as control, the same
reporter construct but without the XRE (pT81) was used. Cells
were then treated with DMSO (0.1%), TCDD (10nM) or 5F 203
(1mM). TCDD was used as a prototypic compound activator of
CYP1A1 transcription and included as a positive control. As shown
in Figure 6A, in MCF-7 cells transfected with pTX.Dir, a 15-fold
induction of luciferase activity was observed with TCDD, and 5F
203 treatment similarly resulted in a 15-fold induction. However,
when AH
R100 cells were transfected with XRE and treated with 5F
203 (1mM), XRE-luciferase activity was demonstrated to be only
approximately 1.7-fold higher than control. No induction in
luciferase activity was observed when cells transfected with pT81
were treated with 5F 203 (1mM) or TCDD (10nM). Similar results
were obtained when cells were transfected with a fragment of
mouse native CYP1A1 promoter (inclusive of four dioxin
responsive elements (DREs)) (pGudLuc1.1) (data not shown)
(Garrison et al, 1996). When pTX.Dir-transfected cells were
pretreated with an antagonist of AhR, a-naphthoflavone, before
treatment with 5F 203, luciferase activity was reduced approxi-
mately 25%, suggesting competition between the two ligands for
binding to the AhR (results not shown).
In order to compare protein/DNA complex formation on the
XRE of CYP1A1 promoter after treatment with 5F 203 in MCF-7
and AH
R100 cells, electrophoretic mobility shift assays were
performed. Previous reports from our laboratory (Loaiza-Pe ´rez
et al, 2002) described that, in MCF-7 cells, three protein/DNA
complexes were found in nuclear extracts of control cells, although
the intensity of the uppermost complex was lower than the others
(Figure 6B, lane 1). 5F 203 (1mM) treatment for 1h (lane 3) caused
a 15-fold induction of the binding of the uppermost complex. This
induction exceeded that afforded by TCDD (10nM, 1h) treatment
(lane 2). AH
R100 cells exposed for 1h to 5F 203 (1mM) showed
considerable attenuation of induction (lane 5). When nuclear
extracts from cells treated with 5F 203 (1mM) for 1h were
pretreated with AhR polyclonal antibody (lane 6) or 100 
unlabelled XRE probe (lane 7), the binding of the three complexes
to labelled XRE sequences was greatly diminished. These protein/
DNA complexes did not disappear when nuclear extracts from 5F
203-treated cells were preincubated with 100  unlabelled SP1
oligonucleotide (lane 8) or IgG antiserum (lane 9).
DISCUSSION
We report here that treatment with 5F 203 causes accumulation in
the G1 and S phase, along with growth inhibition in wild-type
MCF-7 cells, but it does not affect cell cycle progression of AH
R100
cells. We also confirm the production of DNA damage in these
sensitive cells (Stevens et al, 2001), whereas the formation of DNA
adducts is significantly reduced in the resistant subclone (Figure 3).
These results corroborate the view that antitumour activity of 5F
203 is highly dependent on functional AhR signalling, whose
impairment results in reduced efficacy of the agent.
Activation of the AhR signalling pathway may be an important
factor determining sensitivity to 5F 203 because it triggers
metabolic transformation of the drug through CYP1A1 into
reactive species damaging DNA. Our data show that exposure of
AH
R100 cells to 5F 203 produces markedly fewer DNA adducts, as
compared to wild-type MCF-7 cells. The chemical structure of
these adducts has not yet been characterised. Computational
studies using frontier molecular orbital calculations point to the
putative reactive species being a nitrenium ion (Dr SE O’Brien,
personal communication), but further studies are required to
confirm this hypothesis and identify the adducts. A more detailed
description of the formation of DNA adducts induced by
benzothiazoles in sensitive cells will be published separately.
MCF-7 cells have proven to be a valuable and extensively used
model for studies involving the AhR and CYP1A1 expression
(Dohr et al, 1995; Wang et al, 1995; Jorgensen and Autrup, 1996).
Experiments reported elsewhere (Yeh et al, 2001) have demon-
strated that resistance to aryl hydrocarbons in AH
R100 cells is a
consequence of decreased expression of the AhR, which results in
impaired induction of CYP1A1 and probably represents an
adaptation to long-term culture with polycyclic aromatic hydro-
carbons (PAHs). This leads to a diminished capacity to activate
PAHs like DMBA, thereby decreasing the level of apoptosis caused
by exposure to PAHs. Apoptosis induced by DMBA could be
blocked by inhibitors of DMBA metabolism such as a-naphtho-
flavone and diosmetin. These data demonstrated that PAH
resistance in these cells is mediated by changes in the signal
transduction pathway which regulates CYP1A1 expression (Ciolino
et al, 2002). Previous reports have demonstrated that the growth-
inhibitory properties of the parent compound, DF 203, were
abrogated when MCF-7 cells were cotreated with an AhR
antagonist like a-naphthoflavone (Chua et al, 2000). These findings
suggested that activation of AhR mediates sensitivity of MCF-7
cells to benzothiazoles. The fact that adriamycin-resistant MCF-7
cells (NCI/ADR-RES cells), which are also deficient in AhR
signalling (Caruso and Batist, 1999), are resistant to benzothiazoles
(Chua et al, 2000) further supports this hypothesis.
Activation of phase I enzymes, such as CYP1A1 and CYP1B1,
usually occurs as a response to promote detoxification of
xenobiotics; however, metabolic enzymes may convert inert
compounds into potentially harmful products. This is the case
for most PAHs, including benzo[a]pyrene, which induces CYP1A1
via the AhR signalling pathway and is metabolised into reactive
Figure 4 5F 203 induces accumulation of cells in S phase. Exponentially
growing cells (MCF-7 and AH
R100) were exposed to either 0.1% DMSO
(control) or 5F 203 (1mM) for 24h, harvested, washed in PBS, and fixed in
70% ethanol. DNA was stained by incubating the cells in PBS containing
propidium iodide and fluorescence measured and analysed as described in
Materials and Methods.
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Burczynski and Penning, 2000) resulting in G1 cell cycle arrest
(Vaziri and Faller, 1997). In contrast, the environmental pollutant
TCDD, which is the most potent AhR agonist, induces CYP1A1 and
modulates CYP1B1 expression in MCF-7 cells (Dohr et al, 1995),
but is not directly genotoxic. It has been hypothesised that TCDD-
induced alterations in estrogen metabolism may lead to increased
generation of reactive oxygen species and consequent induction of
DNA adducts (Wyde et al, 2001).
In addition to selective metabolism, differential modulation of
AhR functions could underlie specific cytotoxicity of the agent.
Activation of the AhR signalling pathway consists of several steps,
including translocation, pairing with nuclear factors, transactiva-
tion of gene transcription and degradation (Rowlands and
Gustaffson, 1997), each of which might be differentially regulated
in different cells. Other proteins, which integrate the function of
the AhR, like heat-shock protein 90 or ARNT, may also be related
to differential sensitivity to 5F 203. For example, Qin et al (2001)
have demonstrated in patients that there is an association of ARNT
splice variants with ER-negative breast cancer, poor induction of
vascular endothelial growth factor under hypoxia, and poor
prognosis. Further studies are necessary to determine, in greater
detail, aspects of the pathway that may be altered in 5F 203-
sensitive cells.
Figure 5 (A) 5F 203 induces CYP1A1 activity in MCF-7 but not in
AH
R100 cells. MCF-7 and AHR100 cells were incubated for 24h with
DMSO (0.1%) and 5F 203 (1mM) for 24h and assayed for CYP1A1 enzyme
activity by EROD assay as described in Materials and Methods. n¼47s.d.
(B) 5F 203 induces CYP1A1 and CYP1B1 mRNA levels in sensitive (MCF-7)
cells. MCF-7 and AH
R100 cells were treated with 5F 203 (1mM) for 24h,
RNA was isolated from control and treated samples and CYP1A1 and
CYP1B1 gene expression were measured by real-time RT–PCR as
described in Materials and Methods. Data are shown as fold induction of
treated cells relative to constitutive expression in control cells (7s.d., n¼7
samples from two independent experiments).
Figure 6 (A) 5F 203 induces binding to the XRE sequence of CYP1A1.
MCF-7 and AH
R100 cells were transfected with XRE-luciferase (pTX.Dir.)
or pT81. A schematic of the respective construct is shown below the panel.
Transfected cells were treated with DMSO, TCDD (10nM) or 5F 203
(1mM) for 9h. XRE-luciferase activity was determined normalizing to the
amount of Renilla reniformis luciferase. The values are expressed as
luciferase levels relative to control. (B) 5F 203 induces protein/DNA
complexes on the XRE sequence of the CYP1A1 promoter. Nuclear
extracts (20mg) prepared from MCF-7 cells treated with 0.1% DMSO (C)
(lane 1), TCDD (10nM, 1h) (lane 2) or 5F 203 (1mM, 1h) (lane 3) were
incubated with labelled XRE sequence derived from the CYP1A1 promoter
for 10min at room temperature. Free and bound DNA were separated as
described in Materials and Methods. In competition experiments, nuclear
extracts from MCF-7 cells treated with 5F 203 (1mM, 1h) were incubated
with 4mg of anti-AhR antibody (lane 6), 100-fold excess of unlabelled XRE
oligonucleotide (lane 7), 100-fold excess of unlabelled Sp1 oligonucleotide
(lane 8) or 4mg of IgG antiserum (lane 9). Protein/DNA complexes from
AH
R100 cells were resolved in the same gel. Nuclear extracts from these
cells (20mg) treated with DMSO (lane 4) or 5F 203 (1mM, 1h) (lane 5)
were incubated with radioactive XRE and resolved by the same procedure.
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